31 results about "Glycocalyx" patented technology

The use of 2'-fucosyllactose in the preparation of a food / drug for promoting intestinal glycocalyx development and preventing intestinal glycocalyx damage caused by lipopolysaccharide (LPS). The use of 2'-fucosyllactose in the preparation of a food / drug for the adjuvant treatment and / or adjuvant prevention of gastrointestinal infections, inflammatory bowel diseases, obesity or allergy caused by glycocalyx damage. Before adherent growth of Caco-2 cells, adding 2'-FL for co-culture with the Caco-2 cells can simulate the intestinal growth and maturation state. In the state, 2'-FL can significantly promote the development of the glycocalyx layer of Caco-2 cells, and can further prevent the glycocalyx layer damage caused by LPS on this basis.

Some embodiments relate to nanoparticle probes for the detection of disease states in a patient or for tissue engineering. In some embodiments, the nanoparticle probe comprises one or more slip bonds that bind to a cell surface structure. In some embodiments, the binding of the nanoparticle probe is selective. In some embodiments, the nanoparticle probe binds to cells having a certain maximum glycocalyx thickness.

The invention provides an application of OPO and a composition thereof in promoting intestinal development. The 1, 3-dioleoyl-2-palmitin disclosed by the invention can be used for up-regulating the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

Tumor glycocalyx may be regarded as a glycan “canopy” above the tumor plasma membrane. Disclosed are methods of treating a neoplastic malignant cell cancer wherein the neoplastic malignant cancer cell has a malignant glycocalyx B. Also disclosed are methods of inducing apoptosis of one or more neoplastic malignant cells and methods of increasing a subject's responsiveness to an immunotherapy wherein the neoplastic malignant cancer cell has a malignant glycocalyx B.

The invention belongs to the field of biosensing and biological interface engineering, and particularly relates to a double-enhanced bionic glycopeptide electrochemical biosensor based on anti-pollution and anti-enzymolysis stability and a preparation method of the double-enhanced bionic glycopeptide electrochemical biosensor. The invention is inspired by glycoprotein in vascular endothelial cell glycocalyx, a novel glycopeptide material capable of enhancing biological pollution resistance and protease hydrolysis resistance stability is constructed by performing glycosylation modification at the C terminal of a polypeptide sequence, and the novel glycopeptide material is applied to a complex biological medium and has remarkable performance superior to that of non-glycosylated peptide.

The invention provides a preparation method and application of a dairy product for promoting development of an intestinal tract glycocalyx layer. Comprising a specific dose of casein phosphopeptides, and can up-regulate the transcriptional levels of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2. Therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The present invention relates to a composition for promoting intestinal development and its use. The composition comprises lactose-N-neotetraose and 3'-sialyllactose. The composition for promoting intestinal development according to the present invention can upregulate the transcription levels of intestinal glycocalyx development-related genes HAS1, HAS2, and HAS3, as well as the transcription level of EXT2, thereby synergistically promoting intestinal glycocalyx development.

The present invention relates to a method for assessing the presence of a kidney disease in a subject, comprising at least one step of detecting in at least one biological sample isolated from said subject the presence of antibodies capable of recognising and binding at least one protein selected from the group consisting of: Podocin, Kirrel1 and PTPRO. Further, the invention relates to a method and a kit for detecting said antibodies.

The invention provides application of cheese protein zymolyte in promoting intestinal development. The casein zymolyte provided by the invention can up-regulate the transcriptional levels of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The invention provides application of casein phosphopeptides in promoting development of intestinal glycocalyx layers and preparing related products. The casein phosphopeptide provided by the invention can up-regulate the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, the transcriptional level of a coding gene has1 of hyaluronic acid synthetase 1, the transcriptional level of a coding gene has2 of hyaluronic acid synthetase 2, the transcriptional level of a coding gene has3 of hyaluronic acid synthetase 3, the transcriptional level of a coding gene ext1 of exosome glycosyltransferase 1 and the transcriptional level of a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

SCGB-based preparations and methods to use these preparations to protect the glycocalyx in medical, veterinary, and cosmetic applications are provided. The secretoglobins (SCGBs) are a family of small secreted globular proteins present in all mammals and sharing conserved structure and thought to share similar immunomodulatory functions. Heparan sulfate proteoglycan proteins (HSPGs) are expressed on the outer membranes of cells and have carbohydrate side chains that, together, make up the glycocalyx. The glycocalyx is a protective layer surrounding all cells, acting as a filter regulating the passage of nutrients into the cell and modifying cell signaling by external factors. There are two major families of HSPGs including syndecans and glypicans, plus several other HSPGs in all mammals. SCGBs bind to, and interact with, HSPGs to further modulate cell signaling and cellular responses to external factors.

This application relates to the use of dexmedetomidine in the preparation of a drug for protecting the glycocalyx structure of lung tissue, a formulation thereof, and its application, belonging to the field of lung injury technology. This application provides a formulation for protecting the glycocalyx structure of lung tissue, the formulation containing dexmedetomidine, which can protect the glycocalyx structure of lung tissue, thereby reducing lung injury and can be used to treat lung injury.

The invention provides formula milk powder as well as a preparation method and application thereof in promoting intestinal protection or repair. The formula milk powder disclosed by the invention comprises cheese protein zymolyte, and transcriptional levels of an encoding gene gpc1 capable of up-regulating phospholipid globulin glycan, an encoding gene has1 of hyaluronic acid synthetase 1, an encoding gene has2 of hyaluronic acid synthetase 2, an encoding gene has3 of hyaluronic acid synthetase 3, an encoding gene ext1 of exosome glycosyltransferase 1 and an encoding gene ext2 of exosome glycosyltransferase 2, therefore, the formation of a protein skeleton of a glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the formation of the glycocalyx layer is further promoted, and the effects of perfecting an intestinal barrier, regulating intestinal flora, improving intestinal health and promoting intestinal protection or repair are achieved.

According to the preservation method for the glycocalyx ultrastructures of podocytes, endothelial cells and epithelial cells, a high-pressure freezing instrument and a freezing replacement instrument are adopted, millisecond-level glassy state fixation of a sample is achieved through physical freezing, low-temperature dehydration is combined, and the dual problems of chemical damage and charge interference are effectively avoided; the shape preservation effect of glycocalyx of glomerular podocytes, glomerular endothelial cells and small intestine epithelial cells is remarkably improved, the thickness and spatial arrangement of the glycocalyx are close to the physiological state, and dangerous chemicals are prevented from being used.

Provided are modified cells that can alter the glycocalyx of cancer cells. The modified cells include modified lymphocytes that have a one or more plasma membrane-coupled glycocalyx-editing enzymes. The modified lymphocytes include modified immune cells. The modified immune cells include T cells, natural killer cells, macrophages and dendritic cells. The modified immune cells may also express a chimeric antigen receptor. Methods of using the modified cells to alter the glycocalyx of cancer cells, and for cancer therapy, are also provided.

The present invention provides a method of predicting one or more characteristics of endothelial cell glycocalyx in a subject wherein the method comprises measuring the corresponding one or more characteristics of red blood cell glycocalyx from the subject. This is useful in the diagnosis and monitoring of diseases associated with endothelial cell damage.

The invention belongs to the technical field of medical application, and particularly relates to application of dimethyl trisulfide or pharmaceutically acceptable salt thereof in preparation of drugs for preventing or treating microvascular diseases. The invention provides an application of dimethyl trisulfide or pharmaceutically acceptable salts thereof in preparation of drugs for preventing or treating microvascular diseases. Experiments prove that dimethyl trisulfide has a remarkable protective effect on microvascular diseases, can up-regulate the expression of a silence information regulatory factor 1 so as to up-regulate the expression of exosome 1, and can reduce the expression of a phosphorylation nuclear factor-kappa B P65 so as to repair the glycocalyx layer. Results show that dimethyl trisulfide has good effects of preventing and treating microvascular diseases.

Compositions and methods are provided herein for treating intestinal glycocalyx dysfunction. The composition can comprise a chito-oligosaccharide (COS), and optionally a human milk oligosaccharide (hMO) in an amount sufficient to maintain an intestinal glycocalyx and a pharmaceutically acceptable carrier. The composition can be formulated as an oral dosage form or a parenteral dosage form. The method can comprise identifying intestinal glycocalyx dysfunction in the subject. The method can further comprise administering to the subject a COS in an amount and at a frequency sufficient to prevent, stabilize and reverse damage in the intestinal glycocalyx.

The invention provides application of lactoferrin and a composition thereof in promoting intestinal development. The lactoferrin provided by the invention can up-regulate the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, the transcriptional level of a coding gene has1 of hyaluronic acid synthetase 1, the transcriptional level of a coding gene has2 of hyaluronic acid synthetase 2, the transcriptional level of a coding gene has3 of hyaluronic acid synthetase 3, the transcriptional level of a coding gene ext1 of exosome glycosyltransferase 1 and the transcriptional level of a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The invention discloses a traditional Chinese medicine external preparation for preventing picc-related venous thrombosis and a preparation method of the traditional Chinese medicine external preparation, and relates to the technical field of traditional Chinese medicine external preparations. The carrier system comprises a mesoporous silica core, a shear force-body temperature double-response hydrogel middle layer and a pH-responsive gradient cross-linked calcium alginate shell. According to the present invention, with the triple targeting strategy and the multi-signal response carrier system, the precise enrichment and the dynamic release according to the pathological stage of the drug at the thrombus good-onset site can be achieved, and the problems of insufficient targeting and mismatching of the drug release time sequence of the traditional preparation can be solved; the modified traditional Chinese medicine components have the effects of repairing the glycocalyx layer, inhibiting inflammation and specifically resisting thrombus, and the limitation of a traditional extraction process is broken through; the intelligent response matrix is combined with the photo-thermal regulation and transdermal optimization technology, so that the medicine permeation and the skin safety are balanced; according to the preparation process of the carrier, through precise regulation and directional modification, the targeted recognition and controlled release performance is remarkably enhanced, and a new safe and efficient prevention strategy is provided for clinic.

The present invention relates to the fusion proteins against a glycocalyx, found to be associated with several human post-translational modified proteins linked to cancer cell lines. The fusion proteins of the present invention are able to bind only to sialylated glycosphingolipids and sialylated glycoproteins and well as their independent constituents the monosaccharide sugars such as neu5ac, galnac and gal that constitute the glycocalyx. The products claimed can be used for diagnosis and treatment of various cancers. Apoptosis via Caspase 3 occurs in cancer cells when the fusion protein bound to targets is sequestered in lysosomes. The fusion protein is not seen in any other organelle of the cell except for lysosomes.

The invention relates to the technical field of biology, in particular to application of a glycocalyx injury marker SDC-1 serving as a biomarker of ANCA-related vasculitis in the renal inflection active period. The invention discloses a biomarker capable of being used for early diagnosis and treatment scheme selection of ANCA-related vasculitis in the active period of renal inflection. The invention discloses a specific detection method for early diagnosis of ANCA-related vasculitis in the active period of renal inflection. According to the invention, high-precision and non-invasive early diagnosis of ANCA-related vasculitis in the active period of renal inflection can be realized, and the method has important significance for judging and predicting the progress of ANCA-related vasculitis renal inflection.

The application discloses a composite drug sustained-release system based on a biomimetic glycocalyx coating and a medical catheter. The sustained-release system comprises, in sequence, an adhesion layer, a drug storage layer and a biomimetic glycocalyx coating arranged on the surface of a base. The adhesion layer is formed by in-situ polymerization of polyphenols. The drug storage layer embeds active drugs through hydrophobic or amphiphilic polymers. The biomimetic glycocalyx coating simulates the structure of vascular endothelium and is formed by cross-linking of modified polyethylene glycol and biological macromolecules through polyphenols and metal ions. The application can realize self-repairing of damage by using the double cross-linking network of the biomimetic glycocalyx coating, and can synergistically regulate drug release kinetics through a high hydration physical barrier and the storage layer, thereby significantly reducing the friction coefficient of intervention, and also endowing the medical catheter with properties such as antithrombosis and drug sustained release, effectively inhibiting initial burst release of drugs and prolonging the release period, and significantly improving the mechanical resistance, biocompatibility and safety of the medical catheter.

The present invention relates to a method for assessing the presence of a kidney disease in a subject, comprising at least one step of detecting in at least one biological sample isolated from said subject the presence of antibodies capable of recognising and binding at least one protein selected from the group consisting of: Podocin, Kirrel1 and PTPRO. Further, the invention relates to a method and a kit for detecting said antibodies.

The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and / or reducing inflammation and / or oxidative damage, as well as related compositions, kits, and methods.

The application provides application of lactoferrin and a composition thereof in promoting intestinal development. The lactoferrin of the application can up-regulate the transcription level of a phospholipid globulin polysaccharide coding gene gpc1, a hyaluronic acid synthase 1 coding gene has1, a hyaluronic acid synthase 2 coding gene has2, a hyaluronic acid synthase 3 coding gene has3, an exosin glycosyltransferase 1 coding gene ext1 and an exosin glycosyltransferase 2 coding gene ext2, thereby promoting development of a protein skeleton of a glycocalyx layer, synthesis of hyaluronic acid, synthesis of heparan sulfate, further promoting development of the glycocalyx layer, and achieving the effects of perfecting an intestinal barrier, regulating intestinal flora and improving intestinal health.

A marker having excellent sensitivity and specificity to pancreatic cancer and intraductal papillary mucinous neoplasms. Also, a kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms to detect the marker, and a method for evaluating a metastasis of a pancreas cancer cell by using the marker. The marker for pancreatic cancer and intraductal papillary mucinous neoplasms according to the present invention comprises one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein. The kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms according comprises an antibody to one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein.

The present disclosure provides, inter alia, compositions and methods for treating diseases and conditions (such as skeletal diseases) using glycocalyx-modified mesenchymal stem cells. According to some aspects, provided herein are compositions and methods to improve tissue colonization of intravascularly administered human MSCs and, thereby, optimize the intended biologic benefit(s) for any clinical indication where MSCs are utilized.

A use of anisodamine or a pharmaceutically acceptable salt thereof in the preparation of a cellular glycocalyx protectant and a use of the anisodamine or the pharmaceutically acceptable salt thereof as a cellular glycocalyx protectant in the restoration and protection of cellular glycocalyx and a cell adhesion junction are provided. The use of the anisodamine or the pharmaceutically acceptable salt thereof in the preparation of cellular glycocalyx protectant also has an effect of protecting the structure and function of an endothelial cell.

The application provides application of casein phosphopeptide in promoting development of a sugar layer of an intestinal tract and preparation of related products. The casein phosphopeptide can up-regulate transcription levels of a coding gene gpc1 of phospholipid globulin polysaccharide, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosin glycosyltransferase 1 and a coding gene ext2 of exosin glycosyltransferase 2, thereby promoting development of a protein skeleton of the sugar layer, synthesis of hyaluronic acid and synthesis of heparan sulfate, further promoting development of the sugar layer, and achieving the effects of perfecting an intestinal tract barrier, regulating intestinal flora and improving intestinal health.